Study to show which is better for oxygen delivery & blood flow among levosimendan or milrinone in coronary artery surgeries

Effects of levosimendan or milrinone on regional cerebral oxygen saturation in patients undergoing off pump coronary artery bypass grafting-A randomized controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/063388

Enrollment

162

Registered

2024-02-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery

Interventions

Intervention1: MILRINONE VS LEVOSIDEMDAN: ANOTHER GROUP WILL RECIEVE MILRINONE INTRAOPERATIVELY Intervention2: INJ LEVOSIMENDAN: This group will receive Levosimendan IV dose 0.1mic/kg/min for 24 hours

Sponsors

INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH

Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) TRIPLE VESSEL DISEASE 2) EJECTION FRACTION 35 - 55%

Exclusion criteria

Exclusion criteria: PATIENT REFUSAL KNOWN ALLERGY TO STUDY DRUGS COMBINED CARDIAC PROCEDURES CONVERSION TO ON PUMP CABG

Design outcomes

Primary

Measure	Time frame
The current study will evaluate the impact of either of drugs on Regional oxygen saturation levels as measured by Somanetics cerebral oxygen monitor.Timepoint: The observations will be noted in intraoperative period, starting with baseline before skin incision, at time of various coronary bypass grafting and post sternotomy closure.	—

Secondary

Measure	Time frame
The current study will evaluate the impact of either of drugs on Cardiac contractility indicesTimepoint: After induction of Anaesthesia & at the end of surgery	—

Countries

India

Contacts

Public ContactDr. Ashish Chouhan

Institute of Post Graduate Medical Education and Research(IPGME&R) - SSKM Hospital

chaitali03@rediffmail.com7020114401

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026